Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

New class of competitive inhibitor of bacterial histidine kinases.

Gilmour R, Foster JE, Sheng Q, McClain JR, Riley A, Sun PM, Ng WL, Yan D, Nicas TI, Henry K, Winkler ME.

J Bacteriol. 2005 Dec;187(23):8196-200.

2.

Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I.

Kulanthaivel P, Kreuzman AJ, Strege MA, Belvo MD, Smitka TA, Clemens M, Swartling JR, Minton KL, Zheng F, Angleton EL, Mullen D, Jungheim LN, Klimkowski VJ, Nicas TI, Thompson RC, Peng SB.

J Biol Chem. 2004 Aug 27;279(35):36250-8. Epub 2004 Jun 1.

3.

Kinetic and mechanistic analyses of new classes of inhibitors of two-component signal transduction systems using a coupled assay containing HpkA-DrrA from Thermotoga maritima.

Foster JE, Sheng Q, McClain JR, Bures M, Nicas TI, Henry K, Winkler ME, Gilmour R.

Microbiology. 2004 Apr;150(Pt 4):885-96.

PMID:
15073298
4.

Glycopeptide carboxamides active against vancomycin-resistant enterococci.

Zweifel MJ, Snyder NJ, Cooper RD, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ.

J Antibiot (Tokyo). 2003 Mar;56(3):289-95.

5.

Mechanism of action of oritavancin and related glycopeptide antibiotics.

Allen NE, Nicas TI.

FEMS Microbiol Rev. 2003 Jan;26(5):511-32. Review.

6.

Vancomycin tolerance induced by erythromycin but not by loss of vncRS, vex3, or pep27 function in Streptococcus pneumoniae.

Robertson GT, Zhao J, Desai BV, Coleman WH, Nicas TI, Gilmour R, Grinius L, Morrison DA, Winkler ME.

J Bacteriol. 2002 Dec;184(24):6987-7000.

7.

Genome of the bacterium Streptococcus pneumoniae strain R6.

Hoskins J, Alborn WE Jr, Arnold J, Blaszczak LC, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu DJ, Fuller W, Geringer C, Gilmour R, Glass JS, Khoja H, Kraft AR, Lagace RE, LeBlanc DJ, Lee LN, Lefkowitz EJ, Lu J, Matsushima P, McAhren SM, McHenney M, McLeaster K, Mundy CW, Nicas TI, Norris FH, O'Gara M, Peery RB, Robertson GT, Rockey P, Sun PM, Winkler ME, Yang Y, Young-Bellido M, Zhao G, Zook CA, Baltz RH, Jaskunas SR, Rosteck PR Jr, Skatrud PL, Glass JI.

J Bacteriol. 2001 Oct;183(19):5709-17.

8.

Gene disruption studies of penicillin-binding proteins 1a, 1b, and 2a in Streptococcus pneumoniae.

Hoskins J, Matsushima P, Mullen DL, Tang J, Zhao G, Meier TI, Nicas TI, Jaskunas SR.

J Bacteriol. 1999 Oct;181(20):6552-5.

9.

Enzymatic deacylation of teicoplanin followed by reductive alkylation: synthesis and antibacterial activity of new glycopeptides.

Snyder NJ, Cooper RD, Briggs BS, Zmijewski M, Mullen DL, Kaiser RE, Nicas TI.

J Antibiot (Tokyo). 1998 Oct;51(10):945-51.

10.

Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.

Rodriguez MJ, Snyder NJ, Zweifel MJ, Wilkie SC, Stack DR, Cooper RD, Nicas TI, Mullen DL, Butler TF, Thompson RC.

J Antibiot (Tokyo). 1998 Jun;51(6):560-9.

11.

Historical yearly usage of vancomycin.

Kirst HA, Thompson DG, Nicas TI.

Antimicrob Agents Chemother. 1998 May;42(5):1303-4. No abstract available.

12.

Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance.

Nicas TI, Zeckel ML, Braun DK.

Trends Microbiol. 1997 Jun;5(6):240-9. Review.

PMID:
9211645
13.
14.

Tripeptide LY301621 and its diastereomers as methicillin potentiators against methicillin resistant Staphylococcus aureus

Eid CN, Halligan NG, Nicas TI, Mullen DL, Butler TF, Loncharich RJ, Paschal JW, Schofield CJ, Westwood NJ, Cheng L.

J Antibiot (Tokyo). 1997 Mar;50(3):283-5. No abstract available.

15.

Tripeptide LY301621 and its diastereomers as methicillin potentiators against methicillin resistant Staphylococcus aureus.

Eid CN, Halligan NG, Nicas TI, Mullen DL, Butler TF, Loncharich RJ, Paschal JW, Schofield CJ, Westwood NJ, Cheng L.

J Antibiot (Tokyo). 1997 Mar;50(3):283-5. No abstract available.

16.

Structural modifications of glycopeptide antibiotics.

Malabarba A, Nicas TI, Thompson RC.

Med Res Rev. 1997 Jan;17(1):69-137. Review. No abstract available.

PMID:
8979249
17.
18.

Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.

Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Zweifel MJ, Wilkie SC, Rodriguez MJ, Thompson RC, Cooper RD.

Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9.

19.

Solid-Phase Total Synthesis of Bacitracin A.

Lee J, Griffin JH, Nicas TI.

J Org Chem. 1996 Jun 14;61(12):3983-3986.

PMID:
11667271
20.

Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity.

Cooper RD, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ, Huff BE, Thompson RC.

J Antibiot (Tokyo). 1996 Jun;49(6):575-81.

21.

Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.

Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Stratford RE, Cooper RD.

Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. Erratum in: Antimicrob Agents Chemother 1996 May;40(5):1330.

22.

beta-Lactamase inhibitors derived from N-tosyloxy-beta-lactams.

Teng M, Miller MJ, Nicas TI, Grissom-Arnold J, Cooper RD.

Bioorg Med Chem. 1993 Aug;1(2):151-4.

PMID:
8081845
23.

In-vitro synergy and mechanism of interaction between vancomycin and ciprofloxacin against enterococcal isolates.

Unal S, Flokowitsch J, Mullen DL, Preston DA, Nicas TI.

J Antimicrob Chemother. 1993 May;31(5):711-23.

PMID:
8335499
24.

Inhibitors of two-component signal transduction systems: inhibition of alginate gene activation in Pseudomonas aeruginosa.

Roychoudhury S, Zielinski NA, Ninfa AJ, Allen NE, Jungheim LN, Nicas TI, Chakrabarty AM.

Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):965-9.

25.

Modes of action and inhibitory activities of new siderophore-beta-lactam conjugates that use specific iron uptake pathways for entry into bacteria.

Brochu A, Brochu N, Nicas TI, Parr TR Jr, Minnick AA Jr, Dolence EK, McKee JA, Miller MJ, Lavoie MC, Malouin F.

Antimicrob Agents Chemother. 1992 Oct;36(10):2166-75.

26.

Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.

Nicas TI, Cole CT, Preston DA, Schabel AA, Nagarajan R.

Antimicrob Agents Chemother. 1989 Sep;33(9):1477-81.

27.

Characterization of vancomycin resistance in Enterococcus faecium and Enterococcus faecalis.

Nicas TI, Wu CY, Hobbs JN Jr, Preston DA, Allen NE.

Antimicrob Agents Chemother. 1989 Jul;33(7):1121-4.

28.

Cloning and characterization of elastase genes from Pseudomonas aeruginosa.

Schad PA, Bever RA, Nicas TI, Leduc F, Hanne LF, Iglewski BH.

J Bacteriol. 1987 Jun;169(6):2691-6.

29.

Expression in Escherichia coli and function of Pseudomonas aeruginosa outer membrane porin protein F.

Woodruff WA, Parr TR Jr, Hancock RE, Hanne LF, Nicas TI, Iglewski BH.

J Bacteriol. 1986 Aug;167(2):473-9.

30.
31.

The role of exoenzyme S in infections with Pseudomonas aeruginosa.

Nicas TI, Bradley J, Lochner JE, Iglewski BH.

J Infect Dis. 1985 Oct;152(4):716-21.

PMID:
2995500
32.

Role of exoenzyme S in chronic Pseudomonas aeruginosa lung infections.

Nicas TI, Frank DW, Stenzel P, Lile JD, Iglewski BH.

Eur J Clin Microbiol. 1985 Apr;4(2):175-9.

PMID:
2988945
33.

The contribution of exoproducts to virulence of Pseudomonas aeruginosa.

Nicas TI, Iglewski BH.

Can J Microbiol. 1985 Apr;31(4):387-92.

PMID:
2988728
34.

Genetic approaches to study Pseudomonas aeruginosa protein antigens.

Nicas TI, Iglewski BH.

Adv Exp Med Biol. 1985;185:223-32.

PMID:
3000148
35.

Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa.

Nicas TI, Iglewski BH.

Antibiot Chemother (1971). 1985;36:40-8.

PMID:
2988426
38.
39.

Outer membrane proteins of Pseudomonas aeruginosa serotype strains.

Mutharia LM, Nicas TI, Hancock RE.

J Infect Dis. 1982 Dec;146(6):770-9.

PMID:
6183370
40.

Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa.

Hancock RE, Raffle VJ, Nicas TI.

Antimicrob Agents Chemother. 1981 May;19(5):777-85.

Supplemental Content

Loading ...
Support Center